Evidence map›Paper›PMID 18330527›Full record

ReviewWiener medizinische Wochenschrift (1946)2008

[Lifestyle drugs in medicine].

Wolfgang Harth, Kurt Seikowski, Barbara Hermes, Uwe Gieler

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Wiener medizinische Wochenschrift (1946), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Wolfgang HarthKlinik für Dermatologie und Phlebologie, Vivantes Klinikum Berlin Friedrichshain, Akademisches Lehrkrankenhaus der Charité - Universitätsmedizin Berlin, Berlin, Germany. wolfgang.harth@vivantes.de
Kurt Seikowski
Barbara Hermes
Uwe Gieler
Charité - Universitätsmedizin Berlin · DEKlinik für Psychosomatik · DEKlinikum im Friedrichshain · DELeipzig University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lifestyle drugs have become an important new group of medications, which are taken by healthy people to increase the individual well-being and quality of life. Nootropics, psychopharmaceuticals, hormones and "ecodrugs" are today the main groups. The wish for eternal youth, beauty and potency is central, and lifestyle medications are also requested to influence cosmetic findings, which are usually simply a result of the natural aging process. Lifestyle drugs seem to be harmless, but the physician must pay attention to possible abuse, side effects, risks and complications. Additionally, however, lifestyle drugs are also frequently used by patients suffering from emotional disorders such as somatoform disorders. Medicalization of physiological life is then expected to solve psychosocial problems, but without success. The use of lifestyle medications in somatoform disorders is contraindicated and psychotherapy or psychopharmacological treatment come first. With this overview article, we would like to make an update of new lifestyle drugs.

Indexed as

Dietary SupplementsHormone Replacement TherapyLife StyleAgingAttitude to HealthBody ImageHumansNootropic AgentsPsychotropic DrugsQuality of LifeSomatoform DisordersNootropic AgentsPsychotropic Drugs

Identifiers

PMID18330527
OpenAlexW168949193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.